Fig. 8. Antisense morpholinos against XHRT1 reduces the expression of glomus and proximal tubule markers. (A) Design of the XHRT1-MO that targets both pseudoalleles. (Bottom) In vivo translation of XHRT1a-eGFP is specifically inhibited by XHRT1-MOs. Embryos were injected with 500 pg of XHRT1-eGFP or eGFP mRNA, alone or in combination with 15 ng of the XHRT1-MO, as indicated. (B-O) Embryos injected with 15 ng XHRT1-MO and ß-galactosidase mRNA analysed with the indicated markers. (B-I) Control and injected sides of XHRT1-MO-injected embryos with decreased XSMP-30, xPDZK1, xWT1 and nephrin expression. (J,K) Transversal sections of XHRT1-MO-injected embryos. (L,M) XHRT1 knockdown has no effect on Evi1 expression. (N,O) Transversal sections of XHRT1-MO-injected embryos. Ep. keratin and N-tubulin expression is unaffected by XHRT1 knockdown. (P) Co-injection of the XHRT1-MO with 500 pg of XHRT1a-mut-MT-hGR mRNA rescues XSMP-30 expression in stage 22 dexamethasone-treated XHRT1-MO-injected embryos. Changes in the expression of XSMP-30 were scored and classified as in Fig. 6A. (Q) Co-injection of 15 ng XHRT1-MO inhibits the effect of overexpression of hGR/Su(H)/Ank (500 pg) on XSMP-30 expression. Injected embryos were dexamethasone treated at stage 22. Changes in the expression of XSMP-30 were classified into two groups (no change or increase, decrease). n, number of embryos analysed; m, medial intermediate mesodermal layer; pn, pronephros; pt, pronephric tubules.